

ANNUAL REPORT

2021



Message from **THE PRESIDENT**



Sébastien Joliat
President of the Board

The year 2021 marks the 10th anniversary of the CANSEARCH Foundation, which was created on June 23, 2011, to promote medical research on childhood cancer. At that time, doctors and medical staff at the bedside of young sick patients often felt helpless in the face of the impossibility of being able to cure all of them and helpless in the face of the important side effects that some would develop in adulthood. Prof. Marc Ansari, head of the Pediatric Onco-hematology Unit at the University Hospitals of Geneva (HUG), noticed this in his practice and decided to gather a motivated and voluntary team to help and bring hope to these young patients.

In view of the very low level of funding for research on childhood cancers, considered as rare diseases, the decision was taken to set up a research platform in Geneva, bringing together researchers from different backgrounds to conduct research projects in close collaboration with the University Hospitals of Geneva (HUG) and the University of Geneva (UNIGE).


From four researchers at the beginning, the platform has grown during this decade to include more than thirty to date, active on more than thirty different studies.

Witnessing this development, which has only been made possible thanks to the incredible trust and magnificent support of our generous and faithful donors, volunteers and partners, I am very honored and happy to have the privilege of chairing the Board of the CANSEARCH Foundation, after the invaluable work done by Me Robert Hensler, whose mandate as Chairman of the Board ended at the end of 2020, as well as that of the Vice-Chairwoman, Ms. Céline Denizot. I would like to thank them for their time and expertise.

I am looking forward to continuing this great challenge with all of you in this new decade, so that more and more children affected by this terrible disease can enjoy a better life!

With thanks and gratitude for all that you do for CANSEARCH!

Message from **THE FOUNDER & DIRECTOR**



Professor Marc Ansari

Founder and Director of the CANSEARCH Foundation for 10 years. Head of the Pediatric Oncology and Hematology Unit at the HUG. Head of the CANSEARCH research platform in pediatric oncology and hematology of the UNIGE.

The gratitude of Prof. Marc Ansari,
founder, to all those involved in
CANSEARCH

We have left behind the year 2020 and the difficulties it brought us due to the Covid-19 health crisis to enter the year 2021 full of hope, but the global crisis has unfortunately not left us any respite!

The medical research on pediatric cancers conducted by the CANSEARCH research platform in pediatric oncology and hematology has not been spared by this situation, as we all have.

Our international partners (hospitals, medical centers, research institutes, etc.) have seen their pace of work decrease dramatically, which in turn has caused significant delays in the continuation of our own studies. Some of our suppliers have experienced difficulties in supplying and transporting materials used in our laboratory, while most professional organizations in our fields of expertise have only been able to offer their congresses and training sessions virtually, depriving our researchers of the exchanges that are so essential to their practice. Our fight against cancer has continued despite this and we have been congratulated by the Scientific Committee of the CANSEARCH Foundation for the significant progress and publications of the platform in 2021.

At the same time, during this period of close contact with young children with cancer, we were able to see the extent to which human resilience and the ability to adapt was huge and how hope, courage and mental strength can work miracles. Our patients teach us every day to be ever more humble.

Among these miracles is that of all the people who have trusted us and accompanied us for the past 10 years and what they allow us to accomplish every day: to find the means, through scientific research, to improve the treatments administered to children suffering from cancer in order to offer them an ever greater rate of recovery and a better quality of life when they become adults.

Your support during this second complicated and difficult year has not wavered. You have continued to support us

generously, allowing us to continue our research projects, but also to launch new CANSEARCH 2.0 initiatives, as you will read in this Annual Report. In this year of 2021, our 10th anniversary year, this is the greatest gift you can give us!

THANK YOU to each and every one of you for giving us the means to continue our mission!



10 years of concrete results from the CANSEARCH FOUNDATION



1'500 children in Geneva, Switzerland and worldwide benefit from our research



An increase in the survival rate of children receiving a hematopoietic stem cell transplant from 62% to 85%.



Secondary mortality due to treatment toxicity of children receiving a stem cell transplant decreased from 18.5% in 2007 to 3.5% today in Geneva



30+ active researchers, laboratory technicians, clinical research assistants, study coordinators and students



230 scientific articles published and 270 abstracts presented at international and national conferences since 2011



A contribution to open science (participation in activities with post-compulsory students for their matriculation work, publication of all our research results in open access journals or repositories, creation of the Geneva Biobank in Pediatric Oncology and Hematology (BaHOP) and linkage with the Swiss Childhood Cancer Registry and the Pediatric Tumor Biobank in Pediatric Oncology and Hematology (SPHO) with access from 2022 onwards for all researchers)



70+ medical centers worldwide with whom we

collaborate and whose patients we include in our individualized therapy studies (notably for childhood leukemia and pediatric liver cancer)



Opened the first international randomized study in Europe on individualized prescription according to the genetics of each child receiving Busulfan-based chemotherapy (Bugenes study)



10 institutional and competitive grants obtained (notably from the Swiss National Science Foundation, the Swiss Cancer League and the European Horizon 2020 program)



8 research axes: pharmaco-genomics and individualized therapy, neuroblastoma, liver tumors, hematopoietic stem cell transplantation, brain tumors, hematology, biobank infrastructure and genetic risks of post-treatment complications




Creation of the first national germline DNA biobank at the HUG for children with cancer and its certification by the Swiss Biobanking Platform



+ 30 active research projects, including a project in India



+ More than 20 affiliations with national



and international organizations, including the EPFL, the Sainte-Justine Hospital in Canada and the Institute of Social and Preventive Medicine in Bern



Important affiliations and collaborations at the national and international level with various functions assumed in the committees of various organizations and medical associations ("European Blood and Marrow Transplantation group", "European Society of individualised therapy and pharmacogenetic", "Swiss Society of Toxicology and Clinical Pharmacology", "Swiss Group of pharmacogenomics and individualized therapy", etc.)



Invited to participate at numerous scientific conferences



The finances of the **CANSEARCH FOUNDATION**



Phil Lenz
Treasurer of the Foundation Board

In spite of a turbulent year 2021 due to the health crisis linked to Covid-19 and its consequences on our research activity (mainly an important delay in the progress of our studies), the CANSEARCH Foundation has been very lucky to be able to count on its faithful and generous donors who have renewed their support.

We are very grateful to them and express our deepest gratitude for their precious and indispensable support. Without them, the continuation of our activities would simply not be possible.


The very conservative and cautious financial approach that we have always taken, with in particular the capitalization of sufficient assets to cover the average duration of the budgets of our research projects between 3 and 5 years, has allowed us to go through these two years 2020 and 2021 without having to make sudden and major changes in our activities. We have not had to suffer any major negative financial consequences that would be detrimental to our research.

Please note that our accounts are audited according to the requirements of art. 727a of the Swiss Code of Obligations.

Income statement for the year 2021

	2021 CHF	2020 CHF
Income	4 099 019	1 639 660
Grants, private donations	4 060 969	1 626 967
Others grants, private donations	23 051	-
Subsidies and financial aid, city of Geneva	15 000	12 693
Direct expenses	1 567 563	2 225 540
Laboratory expenses	147 380	205 293
Salaries, wages & other research expenses	1 361 541	1 958 773
Support to research	43 020	45 300
Fixed assets depreciations	15 622	16 174
PROFIT FROM OPERATIONS	2 531 456	-585 880
General and administration expenses	349 003	334 569
Events costs	13 360	1 354
Salaries and other benefits - administration	180 255	224 810
Scientific Committee fees	10 276	12 274
Administrative office costs	24 560	-
General and administration expenses	104 075	77 893
Accounting, audit and consultancy fees	16 478	18 237
EARNINGS BEFORE INTERESTS AND TAXES (EBIT)	2 182 452	-920 449
Financial result	-434	-32 041
Banks fees	-882	-1 022
Other financial revenues	60	98
Exchange variations	388	-31 117
EARNINGS BEFORE FUND AFFECTATION	2 182 018	-952 490
Funds contributions	2 182 018	-952 490
Contribution to the research fund	2 197 642	-
Contribution to the fixed assets depreciations fund	-	6 910
./. Fixed assets depreciations fund reallocation	-2	-
./. Use of the fixed assets depreciations fund	-15 622	-959 400
NET PROFIT	0	0

The Councils and Committees of the **CANSEARCH FOUNDATION**



Founder

Prof. Marc Ansari,
Head of the Paediatric Oncology and Haematology Unit of the HUG

CANSEARCH Foundation's work is carried out by many people, most of whom volunteer their time and expertise to help us achieve our goals. A big thank you for their wonderful involvement!

In 2021, Ms. Nathalie Martens Jacquet, Donor Manager, whom we thank for her work on behalf of CANSEARCH, has decided to take on a new professional challenge. Mrs. Nuria Bermudez, our new Fundraising Officer, whom we welcome, took up her position on March 1, 2022.

For the organization of the 10th anniversary party, we can also count on the precious help of Ann Huber Sigwart and Diane Werren Lodyginsky for our search for raffle prizes, as well as Laurence Bagnoud-Roth who has organized several CANSEARCH charity evenings.

Members of the Board



Sébastien Joliat,
President



Phil Lenz,
Treasurer



Gueric Canonica,
Member



Maurice Machenbaum,
Member



Patricia Hubscher
Eichenberger,
Member

Members of the Scientific Committee



Prof. Jakob Passweg,
President



Prof. Roderick
Skinner



Prof. Sylvain Baruchel



Prof. Urs A. Meyer

General Secretariat



Patricia Legler,
Secretary General
(since 2017)



Nuria Bermudez,
Fundraising Officer
(since 1 March 2022)

Permanent Volunteers



Alix Rivoire



Valérie Steck



Cathy Wintsch



Stephanie Ansari



Gian Cla Pinösch

Honorary Committee

Robert HENSLER, president, Mrs. Martha ARGERICH,
Mr. Guy DEMOLE, Mr. Léonard GIANADDA, Mr. Romain GROSJEAN,
Mrs. Carole HUBSCHER, Families Frédy et Franco KNIE, Mr. Bertrand Levrat,
Mr. Raymond LORETAN, Mrs. Michèle MAUS, Mr. Olivier MAUS, Mr. Pierre MOTTU,
Mr. Claude PICASSO, Mr. Stan WAWRINKA, Mr. Jean ZERMATTEN, ZEP

Some figures on
CANCER IN CHILDREN

Recent data on childhood and adolescent cancer (0-19 years)

1ST CAUSE OF MORTALITY BY DISEASE
in children

Between **250 AND 300 NEW** cases diagnosed per year in 0-15 year olds

50% of diagnoses concern **CHILDREN BETWEEN 1 AND 4 YEARS OF AGE**

LESS THAN 2% of funds raised for cancer research are allocated to pediatric cancers

MORE THAN 80% OF CHILDREN CAN BE SAVED
(compared to 20% 50 years ago)

Approximately **2/3 OF CHILDREN DEVELOP AFTER EFFECTS IN ADULTHOOD**



Appeler le **24543** sur le
téléphone en cas d'absence
du personnel de laboratoire !!!
Laboratory staff thank you
for your phone!

Research projects and their **PROGRESS IN 2021**

INSIGHTS INTO THE PROGRESS OF RESEARCH PROJECTS AFTER 10 YEARS

The CANSEARCH research platform in pediatric oncology and hematology at the University of Geneva, by bringing together more than 30 local and international researchers since 2011, has created 8 research axes (pharmacogenomics and individualized therapy, neuroblastoma, liver tumors, hematopoietic stem cell transplantation, brain tumors, hematology, biobanking, and genetic risks of post treatment complications). More than 30 research projects are currently underway thanks to the 30 or so researchers, students and laboratory technicians who work there. Since its inception, no less than 230 manuscripts and 270 abstracts have been presented at the local, national and international levels, allowing us to disseminate our findings.



THE PHARMACOGENOMICS PROJECT

The global pharmacogenomics project aims to identify biomarkers that will allow for better drug dosing based on the child's genetics, through various studies described below, by individualizing the treatment. These make it possible to link the dose of chemotherapeutic drug (notably Busulfan, the main agent used in the conditioning regimen preparing a child for a hematopoietic stem cell transplant) and its response in the child, in order to decrease the toxicity of treatments and related side effects, and to increase the chances of recovery and survival.

THE FORUM STUDY : childhood lymphoblastic leukemia

This study demonstrated that treatment with radiotherapy was superior to treatment with chemotherapy (with various combinations of drugs) in patients over 4 years of age receiving a stem cell transplant for acute lymphoblastic leukemia. Our research platform now aims to identify patients who are particularly at risk but who may benefit from chemotherapy based on certain genetic markers. Thus, a complementary study to focus on the pharmacogenomics and pharmacokinetics of the chemotherapy and radiotherapy drugs used in the trial is underway. This study is open in 17 different countries and 43 centers in total. It also aims to validate our

previous results obtained in a non-homogeneous cohort of pediatric patients in homogeneous cohorts.

The recruitment of DNA samples from patients has continued into 2021, although it has slowed down considerably due to the covid crisis. Up to September 2021, 1'275 patients (children and adolescents) were recruited for the global FORUM study, among which we were able to collect DNA from 406 children for the "pharmacogenomic" component. This large number has allowed us to send 305 of these DNA samples of sufficient quality and quantity to the Genome Center of the Geneva Biotech Campus for whole genome sequencing up to June 2021. The aim of this project is to identify the genes and their variants associated with different drug responses in young patients undergoing stem cell transplantation in order to be able to associate them favorably later in the clinical approach (genotypic association analysis). The pharmacokinetic analysis of clinical data that we have received from our partners will also allow us to learn more about the influence of the identified genes in the response to treatments administered to sick children. This study was supported by the Swiss National Science Foundation.



THE BUGENES PROJECT: predicting the individualized dose for the child

Thanks to the research conducted by the scientific platform over the last 10 years on a gene involved in the pharmacokinetics of Busulfan, the BUGENES study was able to begin. This is the first prospective and randomized dose prediction study of chemotherapy (Busulfan) in children according to individual genetics in Europe in the context of hematopoietic stem cell transplantation.

Recruitment of DNA samples from children and adolescents for this prospective, national and international, multicenter study began in June 2021, after it received approval from the Research Ethics Commission of the Canton of Geneva in April 2021. This study has also just been opened in the other Swiss transplant centers in Basel and Bern.

It also includes patients receiving another chemotherapeutic agent, Fludarabine. This study will include patients in this research protocol from various medical centers in Canada, France, Italy, Denmark and Switzerland and allow us to study this chemotherapy in addition to Busulfan.

The ultimate goal is to be able to include personalized pharmacogenetic recommendations in future international treatment protocols that will take into account the genetic differences of young patients in order

to reduce toxicities and obtain a better outcome. It will therefore be possible to know in advance which patient will need to receive which dose to have an optimal effect. It should be noted that several scientific articles have been published in 2021 for this study.

MYECHILD STUDY: Childhood Myeloid Leukemias

Myeloid leukemias in children have a much poorer prognosis than lymphoblastic leukemias. This makes research into this rarer disease all the more important. For this international randomized phase III clinical trial on acute myeloid leukemia, the research platform is responsible for the ancillary pharmacogenomic study.

Its goal is to identify certain genetic risk factors associated with the response of acute myeloid leukemia to chemotherapy as well as certain factors related to the incidence of toxicities resulting from chemotherapy used in the treatment of this disease. In addition, the research platform plans to validate previous findings regarding Busulfan genetic variants, such as those found in genes encoding GST enzymes (e.g. GSTA1, GSTM1), in association with hematopoietic stem cell transplantation outcomes. The identification of these genetic risk factors may improve the outcome of current myeloid leukemia treatment by personalizing the treatment, improving the efficacy of the anti-leukemic effect and, on the other hand, reducing treatment-related toxicities.

The main study was launched in April 2016 in the United Kingdom. To date, 6 countries (UK, Australia, New Zealand, France, Ireland and Switzerland) have enrolled a total of 624 patients. The contract for this sub-study between the research platform and the University of Birmingham, which is responsible for the overall study, was signed in June 2020.

A combined statistical analysis will be performed, using information obtained so far from our platform on the one hand, and clinical whole genome sequencing of these patients' data on the other. This will allow us to identify the effectiveness of the treatments, and if necessary their failure (relapses and toxicities).

THE PROJECT IN INDIA (INDALL)

Survival rates for children with cancer have improved dramatically from 20% to 80-90%, but have been limited to developed countries, which account for 20% of children with cancer.

The remaining 80% of children with cancers such as acute lymphoblastic leukemia, one of the most common cancers in children and adolescents, live in low- and middle-income countries such as India and do not have access to this success.

The INDALL project, which started in 2020/2021 after our research platform was able to visit and identify participating centers, thus aims to study, in Indian children, the different genetic markers and their genetic associations (somatic and germline) related to treatment efficacy and toxicity, as well as to evaluate the impact of the occurrence of such early toxicities on quality of life during treatment. Often, a child living far from a medical center will risk death from infection due to treatment side effects, which could be avoided by tailoring the treatment to the child's genetics.

This could be avoided by tailoring the treatment to the child's genetics, so that the survival rate of children with acute lymphoblastic leukemia in India, which is between 30% and 70% (average 50%), could be increased and deaths due to toxicities reduced. Of note that this project is supported by a grant from the Swiss National Science Foundation awarded in March 2021.

THE BIOBANK INFRASTRUCTURE

To overcome the lack of biological samples (saliva, plasma, serum, etc..) of proven quality for the study of rare diseases such as oncology and hematology in children, the 1st biobank for pediatric genetics in this particular field in Switzerland, financed by the CANSEARCH Foundation was set up, initially within the Pediatric

Oncology and Hematology Unit of the University Hospitals of Geneva (the Unit) where the "Pediatric Hematology and Oncology Biobank (BaHOP)" was established in 2016.

The BaHOP has already collected, up to June 2021, 7'000 aliquots of samples from more than 2'000 patients, including some from our other studies such as our pharmacogenomic studies (FORUM and MYECHILD) and has obtained the "VITA" quality accreditation label from the "Swiss Biobanking Platform". Thanks to this, BaHOP is currently listed in the international directory of the BBMRI-ERIC consortium of European biobanks (www.bbmri-eric.eu). In addition, four new research projects using the data and resources stored at the BAHOP have been initiated.

The clinical and biological data collected are centralized in our Biobank Information Management System (BIMS) for patients treated in the Unit and for patients enrolled in sub-studies of international clinical trials. For patients included in the BISKIDS project ("Germline DNA Biobank Switzerland for Childhood Cancer and Blood Disorders") aiming to collect, for the first time, germline DNA from all Swiss survivors of pediatric cancers, clinical data collection is centralized at the Childhood Cancer Research Group (CCRG) of the Institute for Social and Preventive Medicine (ISPM) in Bern. Thanks to a grant from the Swiss National Science Foundation - BIOLINK project, this cooperation has made it possible to establish the first national IT platform to link these resources.



THE LIVER TUMOR PROJECT (RELIVE)

Liver cancer in children is a very rare cancer (1% of all childhood cancers).

The RELIVE project aims to establish, in an international registry never realized before, retrospective data of

children with relapsed or refractory liver cancer, in order to achieve a systematic overview and a statistical evaluation of the different approaches used, to allow the identification of the most promising therapeutic approaches for the future and to build the future international clinical trial of childhood liver cancer (PHITT 2).

This project is the result of a collaboration between the CANSEARCH research platform, the Children's Liver Tumor Group at the HUG, as well as researchers from all over Europe (SIOPEL), Japan (JCCG), Australia and New Zealand, Canada and the United States (the "Children Oncology Group"). It is integrated at the international level in the framework of the international collaboration on hepatic tumors in children (the CHIC consortium) of which we are a member.

The project is currently in the activation phase with 16 countries participating. Test and production versions of the database have been developed at the HUG and approvals according to European regulations for certain countries are in the process of being obtained. Data transfer agreement contracts are being developed with several of the partners, and following presentations of this project at the SIOPE and SIOPEL congresses in the spring of 2021, a first scientific publication is in preparation for the coming months. Already more than 40 patients have been recruited in Geneva thanks to RELIVE in this extremely rare pathology.



THE NEUROBLASTOMA PROJECT

Neuroblastoma is the most common cancer in young children and also one of the most aggressive, contributing significantly to the death of children under 5 years of age. This disease presents, in its advanced forms, a survival rate of less than 50%, and this despite a very intense treatment. The main goal of this project is to discover new therapeutic approaches.

The results obtained so far have shown that PRIMA-1MET (Eprentapopt), a small molecule mainly known to reactivate the p53 tumor suppressor gene, was effective in inducing neuroblastoma cell death "in vitro" and this by mechanisms indirectly related to p53. We were able to identify that the RAS-MAPK signaling pathway was a major target of PRIMA-1MET, inducing its inhibition. The combined use of PRIMA-1MET with other inhibitors of the RAS-MAPK pathway has shown a synergistic effect in some neuroblastoma lines, thus increasing the efficacy of PRIMA-1MET. This last point is important since it could not only reduce the risk of resistance, but also allow the use of lower doses of drugs, thus reducing the risk of side effects. The study of the mechanisms involved in these synergies and "in vivo" experiments are currently underway.

The discovery of the involvement of the RAS-MAPK signaling pathway in response to PRIMA-1MET as well as the synergies obtained with different inhibitors of this same pathway allows us to envisage new therapeutic approaches for this cancer which remains one of the most difficult to treat in children.

THE BRAIN TUMOR PROJECT (HGG-CNS Registry)

Data on young children (< 3 years of age) with pediatric high-grade glioma (HGG), a relatively rare cancer in children, are not systematically collected and analyzed to date, preventing a more thorough understanding of this disease, even though they seem to recover better from this pathology than their older counterparts.

To remedy this, this research project aims to create an international registry that will pool epidemiological, clinical

and molecular data from this group of patients, in order to better understand the frequency of the disease, the histopathological specificities of its subgroups and the molecular alterations it generates.

Through collaboration with the Society of Pediatric Hematology and Oncology Working Group (GPOH HIT-HGG: Switzerland, Germany, and Austria) and the SIOP-Europe Pediatric HGG working group, this registry and future collaborative studies can be set up to improve the clinical management of young children with HGG.

HIGH THROUGHPUT SEQUENCING (IN PARTNERSHIP WITH EPFL)

Acute graft-versus-host disease (aGvHD) is a formidable complication of allogeneic hematopoietic stem cell transplantation used to treat certain leukemias. To address this, this pilot study focuses on the development of predictive biomarkers for early diagnosis and targeted immune modulation. The objective is to predict earlier which patients are likely to develop this disease and to better understand its mechanisms.

In this respect, single cell RNA sequencing performed by EPFL has proven useful in preclinical models of aGvHD to profile the immunological components that lead to T cell alloreactivity.

The discovery of predictive gene expression transcriptomic profiles may allow early detection of aGvHD before its clinical presentation, which is of utmost importance in preventing iatrogenic morbidity.

FOR THE CELEBRATION OF THE 10TH ANNIVERSARY OF CANSEARCH, THE LAUNCH OF NEW INITIATIVES "CANSEARCH 2.0"

The CANSEARCH Foundation has new ambitions to promote medical research in pediatric oncology and hematology in Geneva, but also more widely in French-speaking Switzerland. It plans to support, as of 2022, the initiatives described below, in order to support other important aspects related to its field of expertise and according to its statutes, in addition to supporting the development of the CANSEARCH research platform in pediatric oncology and hematology.

RESEARCH AND MOBILITY GRANTS

A CANSEARCH research grant to support a researcher based in French-speaking Switzerland in pediatric oncology or hematology was launched in January 2022. The grant (CHF 250'000.-) will be awarded every two years and will allow the recipient to carry out a research project in this field of expertise. The selection will be made by the Scientific Committee of the CANSEARCH Foundation, in close collaboration with the Scientific Committee of the Swiss Cancer League.

From 2023 onwards, a CANSEARCH mobility grant (CHF 70'000.-) will be offered to a researcher or clinician in pediatric oncology and hematology established in the French-speaking part of Switzerland for training abroad or to secure a place upon return to the French-speaking part of Switzerland. The idea of this scholarship is to allow the recipient to return to the Lake Geneva region to share his or her expertise.

CANSEARCH EMERGENCY FUND TO HELP FAMILIES IN GENEVA

This will allow patients and their families of the Pediatric Oncology and Hematology Unit of the HUG to have access to certain treatments and drugs that are sometimes too expensive and not reimbursed in Switzerland by health insurance, to participate in experimental studies if necessary abroad in order to benefit from anti-cancer

molecules not yet available in Switzerland (phase I-II studies), to finance genetic analyses not yet reimbursed in Switzerland, a CANSEARCH emergency fund to help families has been created (CANHELP). The initial amount of CHF 100'000 will help to obtain these.

It should be noted that this CANHELP Support Fund will also allow the financing of an increase in the capacity of the Pediatric Hematology Oncology Unit for sick children from the Ukraine who are treated in Geneva (hiring of additional nursing staff, CHF 400,000 for one year).

POSITION OF A DOCTOR SPECIALIZED IN THE FOLLOW-UP OF CANCER SURVIVORS AT THE HUG

The survival rate of children with cancer in Switzerland is improving year after year, reaching more than 85% overall, but unfortunately this beautiful evolution is burdened for survivors of pediatric cancer by many side effects. In this context, a specialized medical follow-up is necessary. To this end, an existing survivor follow-up consultation at the HUG will be reinforced, thanks to the hiring of a doctor whose task will be to continue and perpetuate this support and to secure the passage to adulthood with an appropriate follow-up.



10 candos and other events FOR THE 10 YEARS

Originally planned for Thursday, October 14, 2021 at the Geneva Arena, CANSEARCH's 10th anniversary party has unfortunately had to be moved because of Covid-19. It will take place on September 22, 2022.

Despite this, several actions in which you actively participated and which allowed the foundation to be known by a larger public while raising funds for our mission, marked this jubilee.

The superb CANOURSON where a specially created teddy bear doing various activities was photographed by the students of the Institut Notre-Dame du Lac and entered in a contest, the CANGOLF at the Golf Club of Bonmont gathering amateur players on a beautiful sunny day, the 5th edition of the CANWALK in Gstaad which allowed friends of the foundation to meet and the SWIM4HOPE 2022 during which swimmers threw themselves into the water to reach, in relay swim, the Château de Chillon at the Bains des Pâquis in Geneva.

The CANRUN, which took place in front of the Tulip building where the researchers of the CANSEARCH platform work, allowed young and old alike to run in the area near the children's hospital, while the "Country2Country4Cancer" bicycle race organized by the Union for international cancer control (UICC) gave employees of the Bristol Myers Squibb company the opportunity to perform a great sporting feat in support of the Foundation.


In addition to these events, a breakfast was held at the PACE art gallery in Geneva, a concert by the Espace vocal et instrumental de Carouge (EVIC) at the Saint-Gervais church in Saint-Gervais, a morning of sports at the Eaux-Vives park organized by the EVOLVE fitness studio, a day

of games at TRIPTRAP Escape game, as well as several personal birthdays that included support for our research projects.

We are extremely grateful to everyone involved for making these great initiatives possible!







EVOLVE STUDIO

10 ans
CANSEARCH
 fondation de recherche
 contre le cancer de l'enfant

*L'INTÉGRALITÉ DES RECETTES SERA
 REVERSÉE À LA FONDATION*

COURS DE SPORT
 EN FAVEUR DE CANSEARCH

SAMEDI 12 JUN AU PARC DES EAUX-VIVES
 2 COURS (À 09H30 ET À 10H45)

PLACES LIMITÉES

Inscription au 079 543 01 62 ou par
 mail: edgar@evolestudio.ch

CHF 25.-
 PAR PERS. ET PAR COURS



PUBLISHER

CANSEARCH Foundation
Chemin de Pont-Perrin 6
CH – 1226 Thônex
T. +41 76 679 45 63
info@cansearch.ch
www.cansearch.ch

PHOTOGRAPHERS

@ Backbone Art SA, Julien Gaspoz
@ Laurence l'Huillier
@ Karin Bauzin

LAYOUT

Agence markette – www.markette.ch

DIGITAL COMMUNICATION

Groupe pointprod actua - www.pointprod-actua.group

BANK ACCOUNT FOR YOUR DONATIONS

Beneficiary : CANSEARCH Foundation
Bank : Banque cantonale de Genève (BCGE)
17 Quai-de-l'Île, CP 2251, 1211 Geneva 2
Account number : 5089.79.99
IBAN : CH10 00 78 80 000 50 89 79 99

FINANCIAL PARTNER

Bordier & Cie, Banquiers Privés

bordier | 1844

FOR FURTHER INFORMATION

Patricia Legler
General secretary
patricia@cansearch.ch

Nuria Bermudez
Fundraising officer
nuria@cansearch.ch

TO FOLLOW OUR NEWS,

follow us on our website and social networks:

